ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2696

Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries

Raluca Dumitru1, Elizabeth M.A. Hensor1, Ihsane Hmamouchi2, Paul Emery3, Maxime Dougados4 and Maya H. Buch5, 1University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, 2El Ayachi Hospital, Rabat, Morocco, 3Academic Section of Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, 4Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, 5Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom

Meeting: ACR/ARHP Annual Meeting 2015

Date of first publication: September 29, 2015

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:
28 joints-disease activity score (DAS28) is routinely used in clinical practice
to assess disease activity in rheumatoid arthritis (RA). DAS28, particularly
its subjective components [patient visual analogue scale (VAS), tender joint count
(TJC)] might not always reflect inflammation. No study to date has assessed the
relationship between PRO and the DAS28 components in a large cohort of
patients, among different countries. The main objective of this study is to
assess the associations between patient and physician reported outcomes and the
objective components of DAS28 across different geographical populations, using
the COMORA dataset¹(‘Prevalence of Comorbidities in Rheumatoid Arthritis and
evaluation of their monitoring: results of an international, cross-sectional
study’). The study will also assess the relationship between patient and
physician perception of disease activity, and PRO and number of comorbidities.

Methods:
Demographics, clinical characteristics, including DAS28 and PRO, treatment and
comorbidities were recorded. Using Spearman’s rho, we assessed pairwise
correlations among patient global, patient fatigue, physician global, quality
of life (EQ5D) and the DAS28 components for each country. We then looked at the
inter-relationship of patient/physician reported outcomes. Finally, the correlation
between PRO and comorbidities was calculated.

Results:
3674 patients from 17 countries were included in the analysis (mean age 56
years; 82% female). Mean (SD) DAS28 was moderate at 3.72 (1.55). DAS28, SJC,
TJC and ESR varied significantly between countries. ESR showed very weak
correlation with all PRO for the majority of the countries. SJC correlated
moderately with PRO and the association varied between countries, but showed
good correlation with physician global for almost all assessed countries(r>0.5
for 16/17). TJC had good correlation with patient global, physician global and
EQ5D and showed little variation between countries. TJC and patient fatigue
correlation varied between countries. Patient and physician global correlated
with each other. No significant correlation was found between number of
comorbidities and PRO.

Conclusion:
PROs generally associated well with the more subjective components of DAS28
whilst physician global seemed more consistent with the objective elements and
this was observed across most countries. Geographical variation however was
particularly observed with tender joint and patient-reported fatigue. This
might have implications in the interpretation and applicability of
International clinical trials.

References: 1.Dougados M, Ann Rheum Dis, 2014

Table 1: Ranges of Spearman’s rho coefficients

 

Physician global

Patient global

Fatigue VAS

EQ5D

ESR

-0.15 to 0.57

-0.07 to 0.36

-0.04 to 0.28

-0.35 to 0.02

SJC

0.25 to 0.84

0.13 to 0.61

0.05 to 0.61

-0.58 to -0.13

TJC

0.46 to 0.82

0.32 to 0.71

0.18 to 0.59

-0.56 to -0.32

Patient global

0.33 to 0.83

n/a

0.48 to 0.79

-0.78 to -0.53

Comorbidities

n/a

-0.08 to 0.36

-0.06 to 0.35

-0.25 to 0.01

 


Disclosure: R. Dumitru, None; E. M. A. Hensor, None; I. Hmamouchi, None; P. Emery, None; M. Dougados, None; M. H. Buch, Pfizer Inc, 2,Abbvie, Bristol-Myers Squibb, Roche-Chugai, 5.

To cite this abstract in AMA style:

Dumitru R, Hensor EMA, Hmamouchi I, Emery P, Dougados M, Buch MH. Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/geography-and-association-between-patient-reported-outcomes-and-disease-activity-das28-components-in-patients-with-rheumatoid-arthritis-among-17-countries/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2015

ACR Meeting Abstracts - https://acrabstracts.org/abstract/geography-and-association-between-patient-reported-outcomes-and-disease-activity-das28-components-in-patients-with-rheumatoid-arthritis-among-17-countries/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology